Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids
- 17 January 2007
- journal article
- review article
- Published by Elsevier BV in Prostaglandins & Other Lipid Mediators
- Vol. 83 (3), 188-197
- https://doi.org/10.1016/j.prostaglandins.2007.01.005
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- International Union of Pharmacology XLIV. Nomenclature for the Oxoeicosanoid ReceptorPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- Cysteinyl Leukotrienes and Uridine Diphosphate Induce Cytokine Generation by Human Mast Cells Through an Interleukin 4–regulated Pathway that Is Inhibited by Leukotriene Receptor AntagonistsThe Journal of Experimental Medicine, 2002
- Functional Characterization of Cysteinyl Leukotriene CysLT2 Receptor on Human Coronary Artery Smooth Muscle CellsBiochemical and Biophysical Research Communications, 2001
- Hydroxyeicosanoids Bind to and Activate the Low Affinity Leukotriene B4 Receptor, BLT2Published by Elsevier BV ,2001
- AsthmaNew England Journal of Medicine, 2001
- Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmaticsAnnals of Allergy, Asthma & Immunology, 2000
- A Novel Glutathione Containing Eicosanoid (FOG7) Chemotactic for Human GranulocytesJournal of Biological Chemistry, 2000
- A pilot study examining the role of zileuton in atopic dermatitisAnnals of Allergy, Asthma & Immunology, 1999
- Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced BronchoconstrictionNew England Journal of Medicine, 1998
- Leukotrienes: Mediators of Immediate Hypersensitivity Reactions and InflammationScience, 1983